When taking Suimeikai, special attention should be paid to HLA-B * 5701 gene testing, liver toxicity risk, and drug interactions. The drug contains Abacavir, which may cause fatal allergies and requires genetic screening; Hepatic function should be monitored in patients with hepatitis B infection; Combination therapy with multivalent cationic drugs requires interval administration to avoid reduced efficacy.

1HLA-B * 5701 gene testing

(1) Necessity: Abacavir components can cause hypersensitivity reactions in HLA-B * 5701 positive patients, manifested as fever, rash, difficulty breathing, etc., which can be fatal in severe cases.

(2) Operating standards: The genetic test must be completed before medication. Those with positive results are prohibited from using Suimeikai, while those with negative results should still be alert to delayed type allergic reactions.

2 Liver toxicity monitoring

(1) Risk group: people with hepatitis B/C infection, long-term drinkers and patients with abnormal liver function need to strengthen monitoring.

(2) Management measures: Regular monitoring of ALT/AST during treatment, and monitoring for 6 months after discontinuation of medication; If symptoms such as nausea and jaundice occur, seek medical attention immediately.

3 drug interactions

(1) Multivalent cationic drugs: preparations containing magnesium/aluminum/calcium (such as antacids) should be taken with Suimeikai at an interval of 4 hours to avoid affecting the absorption of Doitavir.

(2) Enzyme inducer: Rifampicin can reduce the blood concentration of Doitavir by 50%. When combined, the dosage should be adjusted to twice daily.